J MED VIROL 润色咨询

JOURNAL OF MEDICAL VIROLOGY

出版年份:1977 年文章数:2103 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:6.8% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission<br>This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0<br>经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:化药<br>经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:试验;新冠;临床<br>经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:新冠;临床<br>经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学<br>经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229375, encodeId=01d312293e52b, content=惊呆了,一下子变成了20+的杂志Q1。目瞪口呆, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17c5724173, createdName=洛洛仔111, createdTime=Wed Jun 29 09:01:34 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141098, encodeId=a1152141098f3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:HIV;病毒学;HPV<br>经验分享:投稿一个月后大修,返修后一个月接收,较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ba1b5490572, createdName=wanzhengwei, createdTime=Tue Jun 06 17:12:34 CST 2023, time=2023-06-06, status=1, ipAttribution=约旦), GetPortalCommentsPageByObjectIdResponse(id=2146897, encodeId=8aca214689e55, content=偏重的研究方向:HIV;感染病学<br>经验分享:今年有投稿的么?一个月了还是under review,着急发啊,虽然影响因子掉下去很快 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1912628487, createdName=2007007, createdTime=Sat Jul 08 00:05:04 CST 2023, time=2023-07-08, status=1, ipAttribution=堪萨斯)]
    2024-03-14 ms9000001232984305 来自广东省

    Initial Submission
    This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission<br>This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0<br>经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:化药<br>经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:试验;新冠;临床<br>经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:新冠;临床<br>经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学<br>经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229375, encodeId=01d312293e52b, content=惊呆了,一下子变成了20+的杂志Q1。目瞪口呆, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17c5724173, createdName=洛洛仔111, createdTime=Wed Jun 29 09:01:34 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141098, encodeId=a1152141098f3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:HIV;病毒学;HPV<br>经验分享:投稿一个月后大修,返修后一个月接收,较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ba1b5490572, createdName=wanzhengwei, createdTime=Tue Jun 06 17:12:34 CST 2023, time=2023-06-06, status=1, ipAttribution=约旦), GetPortalCommentsPageByObjectIdResponse(id=2146897, encodeId=8aca214689e55, content=偏重的研究方向:HIV;感染病学<br>经验分享:今年有投稿的么?一个月了还是under review,着急发啊,虽然影响因子掉下去很快 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1912628487, createdName=2007007, createdTime=Sat Jul 08 00:05:04 CST 2023, time=2023-07-08, status=1, ipAttribution=堪萨斯)]
    2023-09-17 evolsy 来自四川省

    审稿速度:2.0
    经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分

    2

    展开2条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission<br>This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0<br>经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:化药<br>经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:试验;新冠;临床<br>经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:新冠;临床<br>经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学<br>经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229375, encodeId=01d312293e52b, content=惊呆了,一下子变成了20+的杂志Q1。目瞪口呆, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17c5724173, createdName=洛洛仔111, createdTime=Wed Jun 29 09:01:34 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141098, encodeId=a1152141098f3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:HIV;病毒学;HPV<br>经验分享:投稿一个月后大修,返修后一个月接收,较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ba1b5490572, createdName=wanzhengwei, createdTime=Tue Jun 06 17:12:34 CST 2023, time=2023-06-06, status=1, ipAttribution=约旦), GetPortalCommentsPageByObjectIdResponse(id=2146897, encodeId=8aca214689e55, content=偏重的研究方向:HIV;感染病学<br>经验分享:今年有投稿的么?一个月了还是under review,着急发啊,虽然影响因子掉下去很快 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1912628487, createdName=2007007, createdTime=Sat Jul 08 00:05:04 CST 2023, time=2023-07-08, status=1, ipAttribution=堪萨斯)]
    2024-02-29 loe1 来自湖北省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:化药
    经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission<br>This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0<br>经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:化药<br>经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:试验;新冠;临床<br>经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:新冠;临床<br>经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学<br>经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229375, encodeId=01d312293e52b, content=惊呆了,一下子变成了20+的杂志Q1。目瞪口呆, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17c5724173, createdName=洛洛仔111, createdTime=Wed Jun 29 09:01:34 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141098, encodeId=a1152141098f3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:HIV;病毒学;HPV<br>经验分享:投稿一个月后大修,返修后一个月接收,较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ba1b5490572, createdName=wanzhengwei, createdTime=Tue Jun 06 17:12:34 CST 2023, time=2023-06-06, status=1, ipAttribution=约旦), GetPortalCommentsPageByObjectIdResponse(id=2146897, encodeId=8aca214689e55, content=偏重的研究方向:HIV;感染病学<br>经验分享:今年有投稿的么?一个月了还是under review,着急发啊,虽然影响因子掉下去很快 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1912628487, createdName=2007007, createdTime=Sat Jul 08 00:05:04 CST 2023, time=2023-07-08, status=1, ipAttribution=堪萨斯)]
    2024-01-02 ms5000000098138879 来自广东省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向:试验;新冠;临床
    经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission<br>This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0<br>经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:化药<br>经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:试验;新冠;临床<br>经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:新冠;临床<br>经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学<br>经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229375, encodeId=01d312293e52b, content=惊呆了,一下子变成了20+的杂志Q1。目瞪口呆, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17c5724173, createdName=洛洛仔111, createdTime=Wed Jun 29 09:01:34 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141098, encodeId=a1152141098f3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:HIV;病毒学;HPV<br>经验分享:投稿一个月后大修,返修后一个月接收,较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ba1b5490572, createdName=wanzhengwei, createdTime=Tue Jun 06 17:12:34 CST 2023, time=2023-06-06, status=1, ipAttribution=约旦), GetPortalCommentsPageByObjectIdResponse(id=2146897, encodeId=8aca214689e55, content=偏重的研究方向:HIV;感染病学<br>经验分享:今年有投稿的么?一个月了还是under review,着急发啊,虽然影响因子掉下去很快 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1912628487, createdName=2007007, createdTime=Sat Jul 08 00:05:04 CST 2023, time=2023-07-08, status=1, ipAttribution=堪萨斯)]
    2023-12-28 ms8000000268543706

    审稿速度:3.0 | 投稿命中率:75.0
    偏重的研究方向:新冠;临床
    经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission<br>This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0<br>经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:化药<br>经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:试验;新冠;临床<br>经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:新冠;临床<br>经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学<br>经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229375, encodeId=01d312293e52b, content=惊呆了,一下子变成了20+的杂志Q1。目瞪口呆, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17c5724173, createdName=洛洛仔111, createdTime=Wed Jun 29 09:01:34 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141098, encodeId=a1152141098f3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:HIV;病毒学;HPV<br>经验分享:投稿一个月后大修,返修后一个月接收,较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ba1b5490572, createdName=wanzhengwei, createdTime=Tue Jun 06 17:12:34 CST 2023, time=2023-06-06, status=1, ipAttribution=约旦), GetPortalCommentsPageByObjectIdResponse(id=2146897, encodeId=8aca214689e55, content=偏重的研究方向:HIV;感染病学<br>经验分享:今年有投稿的么?一个月了还是under review,着急发啊,虽然影响因子掉下去很快 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1912628487, createdName=2007007, createdTime=Sat Jul 08 00:05:04 CST 2023, time=2023-07-08, status=1, ipAttribution=堪萨斯)]
    2023-12-27 ms8000001944553936 来自广东省

    偏重的研究方向:疫苗;新冠;病毒学
    经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission<br>This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0<br>经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:化药<br>经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:试验;新冠;临床<br>经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:新冠;临床<br>经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学<br>经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229375, encodeId=01d312293e52b, content=惊呆了,一下子变成了20+的杂志Q1。目瞪口呆, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17c5724173, createdName=洛洛仔111, createdTime=Wed Jun 29 09:01:34 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141098, encodeId=a1152141098f3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:HIV;病毒学;HPV<br>经验分享:投稿一个月后大修,返修后一个月接收,较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ba1b5490572, createdName=wanzhengwei, createdTime=Tue Jun 06 17:12:34 CST 2023, time=2023-06-06, status=1, ipAttribution=约旦), GetPortalCommentsPageByObjectIdResponse(id=2146897, encodeId=8aca214689e55, content=偏重的研究方向:HIV;感染病学<br>经验分享:今年有投稿的么?一个月了还是under review,着急发啊,虽然影响因子掉下去很快 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1912628487, createdName=2007007, createdTime=Sat Jul 08 00:05:04 CST 2023, time=2023-07-08, status=1, ipAttribution=堪萨斯)]
    2023-09-19 南大 来自江苏省

    请问这个杂志一审多久?

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission<br>This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0<br>经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:化药<br>经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:试验;新冠;临床<br>经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:新冠;临床<br>经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学<br>经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229375, encodeId=01d312293e52b, content=惊呆了,一下子变成了20+的杂志Q1。目瞪口呆, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17c5724173, createdName=洛洛仔111, createdTime=Wed Jun 29 09:01:34 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141098, encodeId=a1152141098f3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:HIV;病毒学;HPV<br>经验分享:投稿一个月后大修,返修后一个月接收,较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ba1b5490572, createdName=wanzhengwei, createdTime=Tue Jun 06 17:12:34 CST 2023, time=2023-06-06, status=1, ipAttribution=约旦), GetPortalCommentsPageByObjectIdResponse(id=2146897, encodeId=8aca214689e55, content=偏重的研究方向:HIV;感染病学<br>经验分享:今年有投稿的么?一个月了还是under review,着急发啊,虽然影响因子掉下去很快 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1912628487, createdName=2007007, createdTime=Sat Jul 08 00:05:04 CST 2023, time=2023-07-08, status=1, ipAttribution=堪萨斯)]
    2022-06-29 洛洛仔111

    惊呆了,一下子变成了20+的杂志Q1。目瞪口呆

    9

    展开9条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission<br>This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0<br>经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:化药<br>经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:试验;新冠;临床<br>经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:新冠;临床<br>经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学<br>经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229375, encodeId=01d312293e52b, content=惊呆了,一下子变成了20+的杂志Q1。目瞪口呆, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17c5724173, createdName=洛洛仔111, createdTime=Wed Jun 29 09:01:34 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141098, encodeId=a1152141098f3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:HIV;病毒学;HPV<br>经验分享:投稿一个月后大修,返修后一个月接收,较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ba1b5490572, createdName=wanzhengwei, createdTime=Tue Jun 06 17:12:34 CST 2023, time=2023-06-06, status=1, ipAttribution=约旦), GetPortalCommentsPageByObjectIdResponse(id=2146897, encodeId=8aca214689e55, content=偏重的研究方向:HIV;感染病学<br>经验分享:今年有投稿的么?一个月了还是under review,着急发啊,虽然影响因子掉下去很快 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1912628487, createdName=2007007, createdTime=Sat Jul 08 00:05:04 CST 2023, time=2023-07-08, status=1, ipAttribution=堪萨斯)]
    2023-06-06 wanzhengwei 来自约旦

    审稿速度:2.0 | 投稿命中率:50.0
    偏重的研究方向:HIV;病毒学;HPV
    经验分享:投稿一个月后大修,返修后一个月接收,较顺利。

    4

    展开4条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=2193197, encodeId=4e1b219319e1c, content=Initial Submission<br>This submission is under consideration and cannot be edited 这个状态已经一个多星期了,到底是什么意思啊,有没有送审?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dfe5649794, createdName=ms9000001232984305, createdTime=Thu Mar 14 15:50:25 CST 2024, time=2024-03-14, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158128, encodeId=3fb62158128a0, content=审稿速度:2.0<br>经验分享:投稿后1.5个月返回。属于送审后拒稿。问题审稿质量差,2个审稿人,一个稍微有点不专业,一个纯属乱写,编辑没留意见,然后拒稿了。申诉后回复了两句:除审稿人外,编辑也评估过了,缺乏priority……前面有人说“审稿也挺看运气”……感觉确实,不知道IF 12分明年能剩几分, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=32, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLBUoZhM96Ldz6FKld3310hFrqf7ib0kmfg6Vv1ulWibrX7ibVqaU44xFbQvYQI2ApNVOdZ8aKGrLt1Ag/132, createdBy=54765271965, createdName=evolsy, createdTime=Sun Sep 17 12:09:52 CST 2023, time=2023-09-17, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=2190089, encodeId=b921219008959, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:化药<br>经验分享:我的研究工作量比较大,编辑给了一次大修、一次小修,然后接收。总的来说审稿人给的意见都很中肯,也收获了一些新的点。还投过两个工作量比较小的文章,都没有接收,看来期刊对质量还是有一定要求的。希望期刊保持住12分,毕竟势头不错病毒学排名第二的期刊。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=02555536999, createdName=loe1, createdTime=Thu Feb 29 14:13:43 CST 2024, time=2024-02-29, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2178696, encodeId=828d21e869660, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:试验;新冠;临床<br>经验分享:10月投稿,12月初小修,12月底接受,总体速度很快,评审人给的意见中肯, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d1178475316, createdName=ms5000000098138879, createdTime=Tue Jan 02 08:47:16 CST 2024, time=2024-01-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2177791, encodeId=653721e7791f7, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:新冠;临床<br>经验分享:8月底投稿,九月底收到大修意见,11月初修回,12月初接收,半个月online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=16, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e92e8253121, createdName=ms8000000268543706, createdTime=Thu Dec 28 15:26:32 CST 2023, time=2023-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2177620, encodeId=f12721e7620e0, content=偏重的研究方向:疫苗;新冠;病毒学<br>经验分享:v i r o l o g y j o u r n a l都是中科院二区,你没道理一直是中科院三区啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e838263314, createdName=ms8000001944553936, createdTime=Wed Dec 27 21:37:38 CST 2023, time=2023-12-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2158518, encodeId=1761215851875, content=请问这个杂志一审多久?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/06/21/1f01e74e0a64f82ab973c71f4ea8ff19.jpg, createdBy=81da1702580, createdName=南大, createdTime=Tue Sep 19 16:50:05 CST 2023, time=2023-09-19, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=1229375, encodeId=01d312293e52b, content=惊呆了,一下子变成了20+的杂志Q1。目瞪口呆, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=47, replyNumber=9, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e17c5724173, createdName=洛洛仔111, createdTime=Wed Jun 29 09:01:34 CST 2022, time=2022-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2141098, encodeId=a1152141098f3, content=审稿速度:2.0 | 投稿命中率:50.0<br>偏重的研究方向:HIV;病毒学;HPV<br>经验分享:投稿一个月后大修,返修后一个月接收,较顺利。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ba1b5490572, createdName=wanzhengwei, createdTime=Tue Jun 06 17:12:34 CST 2023, time=2023-06-06, status=1, ipAttribution=约旦), GetPortalCommentsPageByObjectIdResponse(id=2146897, encodeId=8aca214689e55, content=偏重的研究方向:HIV;感染病学<br>经验分享:今年有投稿的么?一个月了还是under review,着急发啊,虽然影响因子掉下去很快 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=c1912628487, createdName=2007007, createdTime=Sat Jul 08 00:05:04 CST 2023, time=2023-07-08, status=1, ipAttribution=堪萨斯)]
    2023-07-08 2007007 来自堪萨斯

    偏重的研究方向:HIV;感染病学
    经验分享:今年有投稿的么?一个月了还是under review,着急发啊,虽然影响因子掉下去很快

    3

    展开3条回复
共179条页码: 1/18页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分